Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02561273 · ClinicalTrials.gov registry record · Phase 1
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
A Phase 1 study of Hepatosplenic T-cell Lymphoma and Anaplastic Large Cell Lymphoma, ALK-Positive, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 8
- Study locations
NCT02561273 is a Phase 1 study of Hepatosplenic T-cell Lymphoma and Anaplastic Large Cell Lymphoma, ALK-Positive that has completed, run by University of Nebraska. The registered enrollment target is 54 participants, below the 90-participant average among 12 other Hepatosplenic T-cell Lymphoma trials with a reported enrollment target (40% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT02561273, a Phase 1 study of Hepatosplenic T-cell Lymphoma and Anaplastic Large Cell Lymphoma, ALK-Positive, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 8
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with lenalidomide may be a better treatment for peripheral T-cell non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- DRUG Etoposide
- PROCEDURE Autologous Hematopoietic Stem Cell Transplantation
Study Locations (8)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Stanford Cancer Institute - Palo Alto
Colorado
- University of Colorado Cancer Center, Anschutz Cancer Pavilion - Aurora
Georgia
- Emory University/Winship Cancer Institute - Atlanta
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
Nebraska
- University of Nebraska Medical Center - Omaha
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2015-09-28 |
| Est. Completion | 2020-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02561273
The ClinicalTrials.gov registry entry for NCT02561273 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 12 other Hepatosplenic T-cell Lymphoma trials with a reported enrollment target (40% lower). The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Hepatosplenic T-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT02561273 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Georgia.
Frequently Asked Questions
What is clinical trial NCT02561273 about?
NCT02561273 is a clinical study titled "Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma". This phase I/II trial studies the side effects and best dose of lenalidomide when given together with combination chemotherapy and to see how well they work in treating patients with newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosph...
What is the current status of trial NCT02561273?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2015-09-28. Estimated completion is 2020-11-01.
What conditions does trial NCT02561273 study?
This clinical trial studies the following conditions: Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, ALK-negative, Stage II Angioimmunoblastic T-cell Lymphoma.
What interventions are being tested in trial NCT02561273?
The interventions under investigation include: Cyclophosphamide (DRUG), Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Etoposide (DRUG), Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT02561273?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02561273 being conducted?
This trial has 8 study locations across California, Colorado, Georgia, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatosplenic T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
COMPLETED · Phase 1
-
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
COMPLETED · Phase 1
-
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
COMPLETED · Phase 1
-
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Hepatosplenic T-cell Lymphoma
All registered trials for this condition
Anaplastic Large Cell Lymphoma, ALK-Positive
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.